Compare GoPro Inc (GPRO) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GoPro Inc vs Johnson & Johnson — how do they compare? GoPro Inc trades at $0.69 (market cap $122.03M), while Johnson & Johnson trades at $251.56 (market cap $594.63B). The key difference: Johnson & Johnson is far larger — about 4872.8× GoPro Inc's market cap, and Johnson & Johnson pays a 2.17% dividend while GoPro Inc pays none. Which is the better fit depends on your goals.
| GPRO | JNJ | |
|---|---|---|
Market Cap | $122.03M | $594.63B |
Sector | Technology | Health |
52-Week High | $2.88 | $267.24 |
52-Week Low | $0.64 | $162.98 |
Enterprise Value | $169.98M | $627.57B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoPro (GPRO) trades at $0.6978, down 1.86% on the day, reflecting persistent bearish sentiment amid financial distress. The stock shows a negative technical trend with recent earnings misses and declining revenues. The company is undergoing a strategic review for a potential sale or merger, with the CEO providing $20 million in financing to support operations. Valuation ratios like P/E of 4.56 and P/S of 0.18 appear low, but profitability remains deeply negative with a net income margin of -20.7% and ROE of -236.05%.
The outlook is highly speculative, hinging on the success of the strategic review; a sale could unlock value, but ongoing cash burn and competitive pressures pose significant risks. Investors face a binary outcome: potential upside from a strategic transaction versus substantial downside if the company fails to stabilize.
Johnson & Johnson (JNJ) trades at $253.85, down 1.52% on the day, with a bullish technical signal supported by moving averages. The company reported Q1 2026 earnings of $2.70 per share, beating estimates, and raised its full-year 2026 outlook. Revenue grew 6.6% annually in Q2 2026, driven by strength in Innovative Medicine and new product launches, though MedTech sales slightly missed expectations.
JNJ offers a compelling investment case with a 64-year dividend king status, robust profitability, and raised guidance, but faces risks from patent expirations and competitive pressures. Analyst consensus is bullish with a $281 price target, suggesting ~11% upside, supported by strong institutional confidence and innovation in AI and robotics targeting $100 billion revenue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
